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Abstract
Colorectal cancer (CRC) is one of the most frequent 
neoplasms and an important cause of mortality in the 
developed world. This cancer is caused by both genetic 
and environmental factors although 35% of the varia-
tion in CRC susceptibility involves inherited genetic 
differences. Mendelian syndromes account for about 
5% of the total burden of CRC, with Lynch syndrome 
and familial adenomatous polyposis the most com-
mon forms. Excluding hereditary forms, there is an 
important fraction of CRC cases that present familial 
aggregation for the disease with an unknown germline 
genetic cause. CRC can be also considered as a com-
plex disease taking into account the common disease-
commom variant hypothesis with a polygenic model of 
inheritance where the genetic components of common 
complex diseases correspond mostly to variants of low/
moderate effect. So far, 30 common, low-penetrance 
susceptibility variants have been identified for CRC. Re-
cently, new sequencing technologies including exome- 
and whole-genome sequencing have permitted to add 
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a new approach to facilitate the identification of new 
genes responsible for human disease predisposition. By 
using whole-genome sequencing, germline mutations in 
the POLE and POLD1 genes have been found to be re-
sponsible for a new form of CRC genetic predisposition 
called polymerase proofreading-associated polyposis.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Colorectal cancer (CRC) is caused by both 
genetic and environmental factors although 35% of 
the variation in CRC susceptibility involves inherited 
genetic differences. Mendelian syndromes account for 
about 5% of the total burden of CRC. Excluding he-
reditary forms, there is an important fraction of CRC 
cases that present familial aggregation for the disease 
with an unknown germline genetic cause. Recently, 
new sequencing technologies have permitted to add 
a new approach to identify new genes responsible for 
human disease predisposition. By doing so, germline 
mutations in the POLE  and POLD1 genes have been 
found to be responsible for a new form of CRC genetic 
predisposition.
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INTRODUCTION
Colorectal cancer (CRC) is one of  the most frequent 
neoplasms and an important cause of  mortality in the 
developed world. Approximately 5% of  the popula-
tion develops CRC and this figure is expected to rise 
as life expectancy increases[1]. For 2015, approximately 
473200 new cases are predicted and 233900 individuals 
will die from this disease in Europe[2]. When taking into 
account both genders together, it corresponds to the 
most frequent neoplasm in Spain. Although there has 
been recent progress in CRC clinical management and 
treatment that has permitted to reduce the number of  
cases in the developed countries, it is foreseen that its in-
cidence will increase worldwide with developing nations 
bearing the brunt of  the rise. The incidence of  CRC var-
ies widely between countries, depending on their degree 
of  development and also on the quality of  their cancer 
registries[3]. Around 60% of  cases are diagnosed in the 
developed world[3]. The highest incidence rates are found 
in Australia and New Zealand, North America and Eu-
rope, whereas the lowest rates are registered in Africa 
and South-Central Asia[2] (Figure 1).
CRC survival depends on the stage of  disease at di-
agnosis and typically ranges from a 90% 5-year survival 
rate for cancers detected at the localized stage to 10% 
for people diagnosed of  a distant metastatic cancer[4]. 
The lifetime risk of  CRC in the general population is 
about 5% in Western countries, but the likelihood of  
CRC diagnosis increases progressively with age, being 
more than 90% in individuals over age 50, and 70% of  
these over 65[4].
CRC is believed to develop from polyps, which have 
been traditionally classified as either hyperplastic or ad-
enomatous. Until recently, according to the adenoma-
carcinoma sequence proposed by Vogelstein et al[5] the 
adenoma was considered the exclusive precursor lesion 
while hypeplastic polyps were deemed to have no ma-
lignant potential. However, it is now recognized that 
lesions, formerly classified as hyperplastic, represent a 
heterogeneous group of  polyps with a characteristic ser-
rated morphology, some of  which have a significant risk 
of  malignant transformation through the serrated neo-
plasia pathway[4].
GENETIC AND ENVIRONMENTAL RISK 
FACTORS
As other complex diseases, CRC is caused by both ge-
netic and environmental factors. The role of  environ-
mental factors on colorectal carcinogenesis is indicated 
by the increase in CRC incidence in parallel with eco-
nomic development and adoption of  Western diets and 
lifestyles, responsible for the high incidence of  CRC in 
industrialized countries[7]. Although the majority of  CRC 
occur mostly in industrialized countries, their incidence 
rates are rapidly rising in economically transitioning 
countries in the world[8]. These observations highlight 
the importance of  environmental influences on CRC 
development and suggest that Western lifestyle risk fac-
tors play an important role in the etiology of  the disease. 
However, although environmental causes such as smok-
ing and diet are undoubtedly risk factors for CRC, twin 
studies have shown that 35% of  the variation in CRC 
susceptibility involves inherited genetic differences[9,10]. 
In that sense, a minority of  CRC cases (about 5%) show 
strong familial aggregation and belong to the well-known 
hereditary CRC forms mainly caused by germline muta-
tions in APC, MUTYH and the DNA mismatch repair 
genes[11]. Approximately 30% of  CRC cases show some 
family history of  the disease but do not fit in the previ-
ous category and are regarded as familial CRC, whereas 
a majority of  cases do not show any familial aggregation 
and correspond to sporadic CRC. For instance, familial 
CRC accounted for about 30% of  all CRC cases in an 
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epidemiological study in the Spanish population[12].
HEREDITARY CRC
Mendelian cancer syndromes account for about 5% of  
the total burden of  CRC[11]. The genetic components in-
volved in these less frequent hereditary forms were suc-
cessfully identified using linkage analysis in the past two 
decades and they correspond to rare highly penetrant 
alleles that predispose to CRC. Two major subgroups 
can be clinically divided on the presence or absence of  
colorectal polyposis. An overview of  all CRC syndromes 
is provided in Table 1. The most frequent forms are 
hereditary nonpolyposis colorectal cancer and familial 
polyposis syndrome, which are further described below.
Hereditary Nonpolyposis Colorectal Cancer (HNPCC; 
MIM No.120435), also known as Lynch syndrome, is 
the most common form of  hereditary CRC account-
ing for at least 3% of  all CRC. HPNCC is an autosomal 
dominant syndrome defined clinically by the Amsterdam 
criteria (Table 2), which are used in clinical practice to 
identify individuals at risk for this disease who require 
further evaluation and are based on strong familial ag-
gregation and early onset. It is characterized by early-
onset CRC (mean age at diagnosis, approximately 45 
years), excess synchronous and metachronous colorectal 
neoplasms and right-sided predominance compared to 
sporadic neoplasms. In addition, there is an increased 
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Figure 1  Colorectal cancer in the world. A: Estimated age-standarized incidence rate per 100000 individuals (both genders and all ages); B: Estimated age-stan-
darized incidence and mortality rate per 100000 individuals by genders (data adapted from Ferlay et al[2]).
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Incidence
Mortality
Table 2  Amsterdam criteria in Lynch syndrome
Table 1  Hereditary colorectal cancer genes
incidence of  extracolonic neoplasms (endometrial, small 
bowel, gastric, upper urinary tract, ovarian, brain and 
pancreatic tumors) being endometrial cancer the most 
common malignancy associated with Lynch syndrome. 
Indeed, Lynch syndrome is responsible for approxi-
mately 2% of  all endometrial cancers[13]. The lifetime risk 
for developing CRC in individuals affected with Lynch 
syndrome have been estimated in approximately 66% 
for men and about 43% for women. The cumulative risk 
of  endometrial cancer is approximately 40% and the 
lifetime risk of  endometrial cancer or CRC in women is 
approximately 73%[14]. Lynch syndrome tumors develop 
as a consequence of  defective DNA mismatch repair 
(MMR) associated with germline mutations in the MMR 
genes, including MSH2 on chromosome 2p16, MLH1 
on chromosome 3p21, MSH6 on chromosme 2p16, 
and PMS2 on chromosome 7q11. In addition, germline 
epigenetic inactivation of  MLH1, by hypermethylation 
of  its promoter, can also lead to Lynch syndrome[15]. 
Recently, germline deletions of  the 3’ region of  EPCAM 
gene were found in a subset of  families with Lynch syn-
drome. This deletion leads to promoter hypermetilation 
of  MSH2, located upstream of  the deleted gene[16]. The 
MMR system is necessary to maintaining genomic fidel-
ity by correcting single-base mismatches and insertion-
deletion loops during DNA replication. As a conse-
quence, Lynch syndrome tumors accumulate errors in 
short repetitive sequences, a phenomenon called mic-
rosatellite instability (MSI), which is considered a land-
mark for this disease. It is noteworthy to mention that in 
sporadic MSI CRC cancers, loss of  expression of  MLH1 
due to hypermethilation of  its promoter is a frequent 
event, and it is linked with the somatic mutation V600E 
in the BRAF gene[17].
Familial Adenomatous Polyposis (FAP; MIM No.175100) 
is the most common polyposis syndrome, classically char-
acterized by the development of  hundreds to thousands 
of  adenomatous polyps in the rectum and colon. FAP is 
an autosomal dominant disease and accounts for approxi-
mately 1% of  all CRC cases. In the majority of  patients 
polyps begin to develop during the second decade of  life 
and nearly 100% of  untreated patients will have malignancy 
by ages 40-50 years. Individuals with FAP can also develop 
a variety of  extracolonic manifestations, including cuta-
neous lesions such as fibromas, lipomas, sebaceous and 
epidermoid cysts, facial osteomas, congenital hypertro-
phy of  the retinal pigment epithelium, desmoid tumours 
and extracolonic cancers (tyroid, liver, biliary tract and 
central nervous system)[18]. Duodenal cancer is the sec-
ond most common malignancy in FAP, with a lifetime 
risk of  approximately 4%-12%. Adenomatous polyps are 
also found in the stomach and duodenum, especially the 
periampullary area and can develop into adenocarcinomas. 
After colectomy, periampullary carcinoma is the most 
common malignancy, occurring in approximately 5%-6% 
of  the patients[19]. Some lesions such as skull and man-
dible osteomas, dental abnormalities and fibromas are 
indicative of  the Gardner syndrome, a clinical variant of  
FAP where the extracolonic features are prominent. FAP 
is caused by germline mutations in the APC gene on 
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Gene Chromosome Mendelian pattern Function
Familial adenomatous polyposis APC 5q AD Regulation of canonical Wnt signaling pathway
MUTYH 1p AR Base-excision repair
Hereditary non-polyposis CRC (Lynch syndrome) MLH1 3p AD Mismatch repair
MSH2 2p AD Mismatch repair
MSH6 2p AD Mismatch repair
PMS2 7p AD Mismatch repair
Peutz-Jeghers LKB1 19p AD Regulation of Wnt signaling pathway
Juvenile polyposis SMAD4 18q AD TGFBR signaling pathway
BMPR1A 10q AD TGFBR signaling pathway
Cowden’s disease PTEN 10q AD Negative regulation of PI3K signaling
KLLN 10q AD Apoptotic process
CRC: Colorectal cancer; AD: Autosomal dominant; AR: Autosomal recessive; TGFBR: Transforming growth factor beta receptor; PI3K: Phosphatidylinositol 
3-kinase.
Amsterdam criteria Ⅰ Amsterdam criteria Ⅱ
At least three relatives with CRC; all of the following must be 
met:
At least three relatives with colorectal, endometrial, small bowel, ureter, or renal pelvis 
cancer; all of the following must be met:
One affected individual is a first degree relative of the other 
two 
One affected individual is a first degree relative of the other two
At least two successive generations affected At least two successive generations affected
At least one CRC diagnosed before the age of 50 years At least one tumor diagnosed before the age of 50 years
Familial adenomatous polyposis has been excluded Familial adenomatous polyposis has been excluded
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CRC: Colorectal cancer.
chromosome 5q22, which encodes a tumor suppressor 
protein that plays an important role in the Wnt signaling 
pathway. Most patients have a family history of  colorec-
tal polyps and cancer, but de novo APC mutations are 
responsible for approximately 25% of  cases[11].
APPROACHES TO IDENTIFY GENETIC 
VARIANTS FOR CRC RISK
Among CRC cases of  unknown inherited cause, there 
are large families with a clear positive family history of  
CRC, which are likely caused by highly penetrant risk 
loci. In the last few years, it has been described that ap-
proximately 40%-50% of  CRC families that fulfill the 
Amsterdam Criteria for Lynch syndrome do not show 
evidence of  MMR deficiency. Studying relatives in such 
families showed that CRC risk is lower than in those 
families with Lynch syndrome, that CRC diagnosis is in 
average 10 years later and that there is no increased inci-
dence of  extracolonic malignancies[20,21]. The designation 
of  Familial CRC type X was proposed to describe this 
type of  CRC clustering[20]. Meanwhile, genes responsible 
for this new entity are unknown, and most patients are 
included in the heterogeneous group of  non-syndromic 
familial CRC.
Recently, there have been several efforts to identify 
additional genetic factors that predispose to CRC with 
uneven success. Linkage analysis in affected families 
were able to pinpoint chromosomal regions of  interest 
such as 9q22 and 3q22 but no clear CRC predisposition 
genes were identified after screening for interesting can-
didates within these areas[22,23].
Since the known high-risk syndromes only account 
for a small minority of  CRC cases, there has been an 
intensified search for low-penetrance genetic variants 
that probably underlie part of  the hereditary predis-
position and together with environmental interactions 
are responsible for CRC as a complex disease. There-
fore, the common disease-common variant hypothesis 
has been also considered, being a polygenic model of  
inheritance where the genetic components of  com-
mon complex diseases correspond mostly to variants 
of  low/moderate effect (typically < 1.5-fold increased 
risk) that appeared at an elevated frequency in the 
population (> 5%), each exerting a small influence on 
disease risk. In this regard, case-control genome-wide 
association studies (GWAS) have been more successful 
by discovering up to now 31 common, low-penetrance 
genetic variants involved in CRC susceptibility[24-32] 
(Table 3).
OVERVIEW OF NEW SEQUENCING 
TECHNOLOGIES
Until recently, the Sanger method was the dominant 
approach and gold standard for DNA sequencing[33]. 
Next generation sequencing (NGS), also called massive 
parallel sequencing, is based in sequencing millions of  
DNA fragments at the same time[34]. It consists in a mix 
of  techniques of  DNA shearing, PCR amplification and 
sequencing through modified nucleotides attached to a 
reversible terminator and a fluorophore, which permits 
fluorescent detection with an imaging system. Once the 
fragments are sequenced, they are assembled de novo 
or aligned with a reference genome by bioinformatics 
tools and positions that differ are designated as variants. 
Variants are annotated assigning their position in a gene, 
retrieving frequency information from genetic variation 
databases and categorizing them by their functional class 
(nonsense, missense, synonymous, frameshift, splicing, 
intronic, untranslated regions, regulatory).
The advantage of  NGS comparing with conventional 
Sanger sequencing is that millions of  DNA fragments 
are sequenced at the same time which permits to have 
an entire human genome sequenced in few days, and 
the cost is greatly reduced. However, data analysis that 
includes filtering of  the false positives and prioritiza-
tion of  the candidate variants for the studied phenotypic 
condition is the main bottleneck of  NGS, being time 
consuming and requiring different strategies that will be 
discussed later. Another disadvantage of  NGS is that 
PCR amplification and sequencing reaction steps sys-
tematically introduce mistakes, producing base-calling 
errors and shorter sequenced fragments that difficult 
the mapability to the reference sequence. Due to recent 
technology and variant calling algorithm improvements, 
NGS is probably nowadays more accurate than conven-
tional Sanger sequencing[35]. However, although there 
is a very small error rate associated with NGS, a huge 
amount of  false positives are still detected since millions 
of  variants are sequenced per genome[36]. Thus, after 
data analysis and selection of  the candidate variants it is 
necessary to validate them using a technology with a dif-
ferent systematic error associated, such as conventional 
Sanger sequencing, which increases the costs and time 
of  the analysis.
In order to detect genomic sequence variation by 
NGS, it is possible to sequence the entire genome (whole-
genome sequencing, WGS) or capture and sequence 
only specific regions of  interest (targeted enrichment). 
The most commonly used application for NGS target 
enrichment in the human genome is whole-exome se-
quencing (WES) that captures and amplifies the entire 
protein coding sequence (1% genome), flanking intronic 
regions and some noncoding RNAs[37]. It is a cost effec-
tive approach for detecting rare high penetrance vari-
ants based on the fact that for Mendelian disorders over 
the 85% of  causative mutations are in coding regions. 
One advantage of  WES is that is about much cheaper 
than WGS, which allows sequencing a larger number 
of  samples with better accuracy or coverage. The term 
coverage corresponds to the read depth or depth and 
it is the average number of  times that a nucleotide has 
been sequenced in a different sequencing read. Also, 
the data analysis pipelines are simpler in WES than for 
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Table 3  Genetic variants associated with colorectal cancer susceptibility identified by genome-wide association studies (as for September 2013)
WGS. However, WES need for larger amounts of  DNA 
sample and only covering coding variants are among the 
shortcomings for this technique. It is noteworthy men-
tioning that NGS target enrichment can also be used to 
sequence a panel of  known genes for clinical diagnosis[33] 
or regions of  linkage disequilibrium for a disease.
The election of  individuals to sequence is a critical 
process to take into account for further analysis and will 
depend of  the disease phenotype and pattern of  genetic 
inheritance. Also, it should be noted that is possible to 
obtain good results with NGS when using carefully se-
lected patients in contrast to GWAS, where number of  
cases and controls that are compared needs to be much 
higher in order to obtain statistically significant find-
ings. For diseases with genetic heterogeneity as human 
cancers, different strategies can be used including the se-
lection of  families with strong disease aggregation or se-
quencing sporadic cases with early onset for the disease. 
Both situations are suggestive of  the involvement of  a 
germline predisposition. When focusing in families with 
several affected members, sequencing can be performed 
in several cases in each family and only those shared 
variants will be taken into account. On the other hand, 
if  sporadic early-onset cases are chosen, genes with vari-
ants in different individuals can be selected. Sequencing 
non affected individuals of  the same family can be use-
ful to discard the variants shared with patients, as long as 
the disease has complete penetrance or it is quite likely 
that the non affected individuals will not express the dis-
ease in their lifetime.
Data filtering and prioritization in NGS
Based on several recently sequenced individual genomes 
a pattern has been recognized that, in general, approxi-
mately 3-4 million variants are expected to be found in a 
human genome by WGS[38] and 20000 single nucleotide 
variants are to be found in a human exome by WES[39], 
so it is necessary to do a filtering strategy in order to 
eliminate as many false positives as possible. The first 
filter to apply is for those variants that do not pass a 
coverage threshold (typically 5-10x).
The second filtering process is based on the kind of  
inheritance, penetrance and frequency of  the disease. 
Regarding the inheritance, for monogenic diseases where 
unrelated affected individuals have been sequenced, it is 
necessary to select only the genes that have variants in all 
of  them. If  a disease with genetic heterogeneity is stud-
ied, variants shared between the affected members of  
the same family and not shared by the unaffected ones 
will be chosen. Also, if  dominant inheritance is pres-
ent heterozygous mutations will be expected, whereas 
homozygous or compound heterozygous mutations will 
be selected in the case of  recessive inheritance. How-
ever, variants in the non pseudoautosomal regions of  
X chromosome for dominant inheritance have to take 
into account also. In men, they will be annotated as 
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SNP Region Gene Sample size Effect size
(cases/controls) OR (95%CI)
rs693267 8q24.21 MYC 8264/6206 1.21 (1.15-1.27)
rs4939827 18q21.1 SMAD7 8413/6949 1.18 (1.12-1.23)
rs16892766 8q23.3 EIF3H 18831/18540 1.25 (1.19-1.32)
rs3802842 11q23.1 ? 14500/13294 1.12 (1.07-1.17)
rs4779584 15q13.3 GREM1 7922/6741 1.26 (1.19-1.34)
rs10795668 10p14 ? 18831/18540 1.12 (1.10-1.16)
rs4444235 14q22.2 BMP4 20288/20971 1.11 (1.08-1.15)
rs9929218 16q22.1 CDH1 20288/20971 1.10 (1.06-1.12)
rs10411210 19q13 RHNP2 20288/20971 1.15 (1.10-1.20)
rs961253 20p12.3 BMP2 20288/20971 1.12 (1.08-1.16)
rs6691170 1q41 DUSP10 18185/20197 1.06 (1.03-1.09)
rs10936599 3q26.2 TERC 18185/20197 0.93 (0.91-0.96)
rs11169552 12q13.3 ? 18185/20197 0.92 (0.90-0.95)
rs4925386 20q13.33 LAMA5 18,185/20,197 0.93 (0.91-0.95)
rs1957636 14q22.2 BMP4 24910/26275 1.08 (1.05-1.11)
rs4813802 20p12.3 BMP2 24910/26275 1.09 (1.06-1.12)
rs2736100 5p15.33 TERT 16039/16430 1.07 (1.04-1.10)
rs1321311 6p21 CDKN1A 21096/19555 1.10 (1.07-1.13)
rs3824999 11q13.4 POLD3 21096/19555 1.10 (1.07-1.13)
rs5934683 Xp22.2 SHROOM2 21096/19555 1.07 (1.04-1.10)
rs12080929 1p33 SLC5A9 2317/2447 0.86 (0.78-0.95)
rs11987193 8p12 DUSP4 2317/2447 0.78 (0.70-0.87)
rs10774214 12p13.32 CCND2 11870/14190 1.04 (1.00-1.09)
rs647161 5q31.1 PITX1 11870/14190 1.07 (1.02-1.11)
rs2423279 20p12.3 HAQ1 11870/14190 1.07 (1.03-1.12)
rs11903757 2q32.3 NABP1 15752/21771 1.16 (1.10-1.22)
rs10911251 1q25.3 LAMC1 15752/21771 1.09 (1.06-1.13)
rs3217810 12p13.32 CCND2 13654/16022 1.20 (1.12-1.28)
rs3217901 12p13.32 CCND2 15752/21771 1.10 (1.06-1.14)
rs59336 12q24.21 TBX3 15752/21771 1.09 (1.06-1.13)
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homozygous and it is necessary to select these variants 
too and not filter them out. Regarding variant effect on 
protein, it is assumed that high penetrance mutations 
are causative of  Mendelian disorders with a large effect 
on protein function. Therefore, a positive selection for 
variants with a strong effect on the protein is advised 
including those affecting canonical splice sites, as well as 
frameshift, nonsense and missense mutations.
Proportionally, more deleterious than polymorphic 
variants are expected to be rare so a causative mutation 
is not expected to be present at a high frequency in the 
general population[40]. Thus, variants present at high fre-
quency at reference genetic variation databases can be re-
moved as potential candidates to be causative mutations.
However, many variants can still remain for each in-
dividual as putative causative mutations for the disease 
after filtering. A logical approach to reduce the number 
of  candidate variants is to prioritize the mutations in 
genes previously implicated with the studied disease. 
Also, since the protein products of  genes responsible 
for the same disorder tend to physically interact with 
each other so as to carry out certain biological functions, 
another approach for the prioritization strategy will be 
to include genes interacting with those previously impli-
cated with the studied disease[41]. Finally, knowledge of  
the pathways implicated in a disease can be helpful also 
to prioritize those genes related with those pathways. Af-
ter filtering and prioritization, a list of  candidate variants 
will be available.
Sequencing validation by Sanger sequencing or any 
other PCR technology designed to detect a specific 
nucleotide change is necessary after NGS to confirm 
the prioritized variants and exclude sequencing artifacts. 
Also, segregation analysis in families permits to check if  
a candidate variant segregates correctly with the disease. 
Therefore, affected members need to be carriers and 
non-affected individuals old enough to be expressing the 
disease should be non-carriers in order to find correct 
segregation of  the candidate variant with the studied dis-
ease. Additionally in the case of  hereditary cancer, when 
heterozygous candidate variants with correct segrega-
tion are identified, it is necessary to confirm if  there is 
loss of  the second allele in the tumor DNA in order to 
establish the candidate gene as a tumor suppressor gene. 
Case-control screening studies can also be performed in 
order to identify additional carriers of  the candidate vari-
ants in ample disease cohorts and further demonstrate 
its absence in controls. Finally, functional assessment of  
the candidate variant and affected gene will be also nec-
essary to further confirm the negative effect of  the vari-
ant in the protein and prove its involvement in disease 
development by in vitro studies and animal models.
NEW GENES IDENTIFIED FOR CRC 
GENETIC PREDISPOSITION
New sequencing technologies made available recently 
including exome- and whole-genome sequencing have 
permitted to add a new approach to facilitate the iden-
tification of  new genes responsible for human disease 
predisposition. Indeed, some seminal efforts have been 
already completed very recently for CRC. However, be-
fore these high-throughput technologies have yielded 
results in CRC families, some previous low-throughput 
sequencing studies reported directed screening of  some 
plausible gene candidates for various reasons. Most stud-
ies have not been replicated in additional cohorts and, 
therefore, there is a strong need to further validate them 
before considering these genes as hereditary CRC genes 
perse.
A truncating mutation was found in the CDH1 gene in 
a family with predisposition to CRC and gastric cancer, 
suggesting that germline mutations in this gene could 
contribute to early onset CRC and gastric cancer[42]. 
Later on, the AXIN2 gene, a component of  the Wnt 
signaling, was found to be mutated in a Finnish family 
with severe permanent tooth agenesis and CRC[43]. In a 
subsequent study in patients with unexplained hamarto-
matous or hyperplastic/mixed polyposis, two early-onset 
disease patients were found to have germline muta-
tions in ENG, encoding endoglin, previously associated 
only with hereditary hemorrhagic telangiectasia[44]. This 
study suggested ENG as a new predisposition gene for 
juvenile polyposis, however this gene was found to be 
mutated in an additional study only in patients with ≥ 
5 cumulative lifetime gastrointestinal polyps but not in 
juvenile polyposis[45]. EPHB2 was also evaluated as a 
candidate tumor suppressor gene for CRC and found 
mutated in 3 out 116 population-based familial CRC 
cases, suggesting this gene may contribute to a small 
fraction of  hereditary CRC[46]. In 2009, the GALNT12 
gene was also found mutated in the germline of  6 CRC 
patients[47]. This gene encodes one of  the proteins in-
volved in mucin type O-linked glycosylation and it is lo-
cated in chromosomal region 9q22, previously involved 
in familial CRC. A more recent study detected additional 
deleterious variants in this gene reinforcing its role as 
a new candidate gene for hereditary CRC[48]. Also, an 
inherited duplication affecting the protein tyrosine phos-
phatase PTPRJ and causing epigenetic silencing of  this 
gene was detected in a CRC family without polyposis 
and MMR alteration, being indicative of  its contribu-
tion to a fraction of  hereditary CRC with unknown ba-
sis[49]. Afterwards, BMP4, a gene close to 2 of  the CRC 
genetic susceptibility variants identified by GWAS, was 
also screened in 504 genetically enriched CRC and 3 
pathogenic mutations were identified[50]. Then, it could 
be plausible that some genes identified by CRC GWAS 
could be also involved in hereditary CRC. In 2011, the 
BMPR1A gene, previously involved in juveline polyposis 
and mixed polyposis germline predisposition, was also 
found mutated in familial CRC type X cases, expand-
ing its phenotype also to this CRC hereditary form[51]. 
Finally, Cowden syndrome individuals without germline 
PTEN mutations were found to carry germline muta-
tions in PIK3CA and AKT1, expanding the genetic spec-
1967 February 28, 2014|Volume 20|Issue 8|WJG|www.wjgnet.com
Esteban-Jurado C et al . New genes for colorectal cancer predisposition
trum of  this hereditary CRC condition[52].
Regarding NGS studies to identify new CRC pre-
disposition genes, Palles et al[53] reported very recently 
the identification of  germline mutations in the POLE 
(polymerase (DNA directed), epsilon, catalytic sub-
unit) and POLD1 (polymerase (DNA directed), delta 
1, catalytic subunit) genes in individuals with multiple 
colorectal adenomas, carcinoma or both, using whole-
genome sequencing[54]. POLE and POLD1 encode the 
catalytic and proofreading activities of  the leading-strand 
DNA polymerase ε and the lagging-strand polymerase 
δ. The proofreading capacity of  the exonuclease domain 
is essential for the maintenance of  replication fidelity 
and may act not only on newly misincorporated bases 
but also on mismatches produced by non-proofreading 
polymerases. They identified a heterozygous p.Leu424Val 
missense variant in POLE DNA polymerase in a fam-
ily affected with adenomas and CRC and a p.Ser478Asn 
missense variant in POLD1 in a second family with CRC. 
The same POLD1 p.Ser478Asn variant was also identi-
fied in the affected members of  an independent family. 
These findings were further validated in a screen of  3,085 
individuals with CRC, enriched for a family history of  
colorectal tumors, in which they detected 12 individuals 
with the p.Leu424Val variant in POLE and one addition-
al individual with the pSer478Asn in POLD1. Functional 
assessment supported the importance of  these muta-
tions in POLE and POLD1. Mutagenesis studies of  Polδ 
and Pol3 in yeast showed that the mutation of  the equiv-
alent residue produces a mutator phenotype and loss 
of  the proofreading activity of  the protein[53,55,56]. Also, 
mice expressing proofreading-impaired Pole and Pold1 
in a homozygous state developed spontaneous intestinal 
adenocarcinomas or a spectrum of  cancers[57]. Thus, 
germline variants in POLE and POLD1 predispose to 
individuals to either a multiple colorectal adenoma phe-
notype similar to that observed in MUTYH-associated 
polyposis or a HNPCC phenotype, in which carriers 
develop early-onset CRC. Although additional studies 
will be needed to evaluate these rare germline variants in 
POLD1 and POLE and their associated phenotypes, the 
authors suggest that screening for these variants should 
be considered in patients with an unexplained personal 
or family history of  multiple adenomas, early onset CRC 
or both. On the other hand, carriers are potential candi-
dates for regular and frequent colonoscopic surveillance 
starting at an early age.
Two additional reports using exome sequencing have 
also been published very recently but their results are 
not as solid as those for the polymerase genes previously 
mentioned. A cohort of  50 sporadic CRC patients was 
sequenced including 18 early-onset cases with a relatively 
low coverage in the first study[58]. Variants were biased 
selected when found in a list of  1,138 genes likely to play 
a role in CRC. Further selection to include only those 
genes undergoing bialleic inactivation yielded FANCM, 
LAMB4, PTCHD3, LAMC3 and TREX2 as poten-
tial tumor suppressor candidates. In the second study, 
exome sequencing was completed for 40 familial cases 
from 16 families by selecting distant relatives to decrease 
the number of  shared, non-predisposition variants[59]. 
Data was analyzed firstly by an agnostic search for CRC 
predisposition genes not taking into account a biased 
list of  candidates, and secondly by selecting genes pre-
viously involved in CRC predisposition or within CRC 
linkage regions. Two missense variants in the CENPE 
and KIF23 genes that complied with family segregation 
and belong to regions on chromosomes 1 and 15 for-
merly linked to CRC were considered the more plausible 
candidates for CRC predisposition but additional studies 
are needed to further elucidate their role.
CONCLUSION
CRC is one of  the most frequent neoplasms and an 
important cause of  mortality in the developed world. 
CRC is caused by both genetic and environmental fac-
tors although 35% of  the variation in CRC susceptibility 
involves inherited genetic differences. Mendelian cancer 
syndromes account for about 5% of  the total burden of  
CRC, being Lynch syndrome and familial adenomatous 
polyposis the most common forms. Familial CRC type X 
is an example of  CRC with unknown inherited cause. A 
clear positive family history of  CRC is present (Amster-
dam criteria for Lynch syndrome are fulfilled) although 
MMR is proficient. When considering CRC as a com-
plex disease, low-penetrance genetic variants probably 
underlie part of  the hereditary predisposition together 
with environmental interactions. So far, 30 susceptibility 
variants have been identified for CRC. New sequencing 
technologies made available recently including exome- 
and whole-genome sequencing have permitted to add 
a new approach to facilitate the identification of  new 
genes responsible for human disease predisposition. 
Germline mutations in the POLE and POLD1 genes are 
responsible for a new form of  CRC genetic predisposi-
tion called polymerase proofreading-associated polypo-
sis.
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